FindTrial
Sign In

Randomized prospective studies in esophageal squamous cell carcinoma patients with distant organ metastasis at initial diagnosis: Taxol combined cisplatin chemotherapy alone vs. Taxol combined cisplatin induction chemotherapy followed by concurrent chemoradiotherapy (phase II trial)

Randomized prospective studies in esophageal squamous cell carcinoma patients with distant organ metastasis at initial diagnosis: Taxol combined cisplatin chemotherapy alone vs. Taxol combined cisplatin induction chemotherapy followed by concurrent chemoradiotherapy (phase II trial)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13005027
Enrollment
Unknown
Registered
2013-09-11
Start date
2015-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

A:Taxol combined cisplatin chemotherapy alone
B:Taxol combined cisplatin induction chemotherapy+concurrent chemoradiotherapy

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 70 years old; EOCG score less than 2; Life expectancy longer than 3 months; 2. pathology confirmed esophageal squamous carcinoma; 3. TanyNanyM1 clinical stage, M1 = organ metastasis; only the distant lymph node metastasis and no organ metastasis is not included in this study; 4. no obvious abnormal blood routine, biochemical (WBC 4*10^9/L or higher, PLT 100*10^9/L or higher, HGB acuity 8.0 g/L, ALT, AST, upper limit of normal or less by 2.5 times, CCr acuity 60 ml/min); 5. No sign of esophageal perforation; 6. no other concomitant medical condition requiring treatment (such as acute myocardial infarction, stroke, etc.); 7. No effective allergy to chemotherapy regimen;H. signed informed consent.

Exclusion criteria

Exclusion criteria: 1. history of other tumors; 2. adenocarcinoma, neuroendocrine or small-cell esophageal carcinoma, or other malignant tumors of special or uncertain biological behavior; 3. in pregnant women.

Design outcomes

Primary

MeasureTime frame
Progress Free Survival, PFS;median survival time, MST;1, 2-year over survival;—

Secondary

MeasureTime frame
the toxity and side effect of chemotherapy and CCRT;—

Countries

China

Contacts

Public ContactBenHua Xu
benhuaxu@163.com+86 13696884375

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026